It's the second blow to GSK's cancer drugs portfolio in the space of a week, after the company revealed that its BCMA-targeting drug Blenrep (belantamab mafodotin) failed to meet its objectives in ...

GSK said it acquired an experimental therapy from Chimagen Biosciences that it aims to test in different forms of lupus, and ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

GSK will pay $300 million to acquire a bispecific antibody from Shanghai-based Chimagen Biosciences that it believes has the ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

By Rebecca Robbins The British drug maker GSK said on Wednesday that it would pay up to $2.2 billion to settle most of the lawsuits filed against it by people who claim that they developed cancer ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

Also, it is focusing more on oncology and the immune system, with genetic data to help develop the next generation of drugs. The benefits of these strategies are showing up in GSK's early-stage drugs.

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

U.K. drugmaker GSK on Wednesday cut its vaccine sales guidance for the year, citing lower-than-expected demand. The company said it’s now expecting a low single-digit fall in vaccine sales this ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.